investigator_user
investigator
user
funding
collaborators
pending
menu
bell
message
arrow_up
arrow_down
filter
layers
globe
marker
add
arrow
close
download
edit
facebook
info
linkedin
minus
plus
save
share
search
sort
twitter
remove
user-plus
user-minus
Sign Up for Updates
Map
Countries
Cancer types
All cancers but non-melanoma skin cancer
Bladder
Brain, nervous system
Breast
Cervix uteri
Colorectum
Corpus uteri
Gallbladder
Hodgkin lymphoma
Kaposi sarcoma
Kidney, renal pelvis and ureter
Larynx
Leukaemia
Lip, oral cavity
Liver and intrahepatic bile ducts
Melanoma of skin
Multiple myeloma and immunoproliferative diseases
Nasopharynx
Non-Hodgkin lymphoma
Non-Melanoma skin cancer
Oesophagus
Other pharynx
Ovary
Pancreas
Prostate
Sarcoma
Stomach
Testis
Thymus
Thyroid
Trachea, bronchus and lung
Specialities
Hematology and hematologic malignancies
Palliative Care
Pathology
Pediatric oncology or childhood cancer
Radiation Oncology
Surgery / Surgical oncology
Blog
About
Login
Project leads
Collaborators
The Role of FOXC1 in Basal-Like Breast Cancer
Xiaojiang Cui
1 Collaborator(s)
Funding source
National Cancer Institute (NIH)
Follow
+ Project
+ Post
+ Event
Info
People
Posts
Michael Walter
University of Alberta
Edmonton, Canada
Xiaojiang Cui
Cedars-Sinai Medical Center
Los Angeles, United States
Related projects
Lewis A Chodosh
Minimal Residual Disease and Mechanisms of Breast Cancer Recurrence
Breast
Kornelia Polyak
Targeting intratumor heterogeneity in breast cancer
Breast
Susan Bates
Investigation of the ABC Half-Transporter ABCG2
Breast
Mircea Ivan
Role of Hypoxia-Induced miR-210 in Tumor Metabolism
Breast
Bing Xia
Role of PALB2 in the DNA Damage Response and Cancer Suppression
Breast
Ann Richmond
Chemokine Signals in the Premetastatic Niche Inhibit Metastasis
Breast
Mark I Greene
Carbohydrate Antigenic Biomarkers for Epithelial Cancers
Breast
Marie C. Lee
Development of the Malignancy-Risk Gene Signature Assay for Predicting Breast Cancer Risk
Breast
Fraser Symmans
Development of A Predictive Genomic Diagnostic Test for Survival Benefit from Everolimus (mTOR Inhibitor) Combined with Endocrine Therapy for Metastatic HR+/HER- Breast Cancer
Breast